Life-extending drugs Alpelisib and Trodelvy will benefit 3,500 women a year
Thousands of breast cancer patients in England are to benefit from two new drugs available on the NHS following a U-turn by the health watchdog.
About 3,500 women a year will benefit from life-extending drugs Alpelisib and Trodelvy, which have now been given the green light despite being rejected earlier this year by the National Institute for Health and Care Excellence (Nice).
Subscribe
Login
0 Comments